TY - JOUR
T1 - Cancer vaccines in the era of checkpoint blockade
T2 - the magic is in the adjuvant
AU - Overwijk, Willem W.
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/8
Y1 - 2017/8
N2 - While T cell checkpoint blockade therapy of various cancers yields impressive clinical benefits, most patients are not cured. This is thought to result from insufficient spontaneous tumor-specific T cell responses, a situation that could be remedied with cancer-specific vaccination. Much work is underway to identify cancer-specific antigens, leaving open the question of how to formulate these antigens in a manner that provokes potent cancer-specific T cell responses. In this review I discuss paradigms guiding adjuvant development, and consider what may constitutes a clinically relevant T cell response. I also suggest that adjuvants providing multiple non-redundant signals may be the next frontier in the development of cancer vaccines that provide true clinical benefit when combined with T cell checkpoint blockade.
AB - While T cell checkpoint blockade therapy of various cancers yields impressive clinical benefits, most patients are not cured. This is thought to result from insufficient spontaneous tumor-specific T cell responses, a situation that could be remedied with cancer-specific vaccination. Much work is underway to identify cancer-specific antigens, leaving open the question of how to formulate these antigens in a manner that provokes potent cancer-specific T cell responses. In this review I discuss paradigms guiding adjuvant development, and consider what may constitutes a clinically relevant T cell response. I also suggest that adjuvants providing multiple non-redundant signals may be the next frontier in the development of cancer vaccines that provide true clinical benefit when combined with T cell checkpoint blockade.
UR - http://www.scopus.com/inward/record.url?scp=85027844524&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027844524&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2017.07.015
DO - 10.1016/j.coi.2017.07.015
M3 - Review article
C2 - 28806603
AN - SCOPUS:85027844524
SN - 0952-7915
VL - 47
SP - 103
EP - 109
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -